Team
Our Team
Thomas R. Webb, Ph.D
CEO/CSO
Thomas R. Webb, Ph.D., is Chief Scientific Officer and a principle founder of Wildflower Biopharma, Inc. Webb’s previous experience includes executive leadership roles (VP of R&D for ChemBridge Corporation) where he co-chaired large collaborative drug discovery projects with major pharmaceutical companies (including Pfizer and GSK) as well as acting as Principal Investigator for numerous NIH grant supported investigator-initiated drug discovery projects, while serving as Director, Medicinal Chemistry in the Center for Chemical Biology in SRI Biosciences and St. Jude Children’s Research Hospital...
Sven H. Wagner, Ph.D
CBO
Sven H. Wagner, Ph.D., is the Chief Business Officer of Wildflower Biopharma, Inc.and responsible for global business efforts by leveraging therapeutic innovation sustainable towards improving patients’ life.He brings +20 years of experience in the biopharmaceutical and CRO/CMO industries in different leadership functions, such as licensing, business and corporate development, sales andmarketing, alliance management and always providing support for numerous collaborative global...
Steve Morris, MD
CMO
Steve Morris is a board-certified internist (Univ. of Texas SW HSC) and medical oncologist (Yale University School of Medicine). Dr. Morris served on the staff at St. Jude Children’s Research Hospital for 25 years. In addition to working as a clinician, Dr. Morris led a basic/translational research laboratory at St. Jude that discovered and characterized oncogenes that cause a variety of human cancers, most notably anaplastic lymphoma kinase (ALK).
Dr. Morris began transitioning from academia to industry in 2007, co-founding the molecular diagnostics company Insight Genetics...
Mads Riegel
Vice President of Operations
Mads Riegel is the Vice President of Operations at Wildflower BioPharma Inc. Mads' experience includes startup entities and an executive leadership in his family business in Norway. As the BD Director at Venomyx, Mads established scientific and strategic business partnerships with several entities and led efforts to generate alternate income and funding for the company. While there, he also compiled one of the most comprehensive sequencing databases for venomous snake proteins. In his earlier days,.......